A Study to Compare the Press Fit Condylar (P.F.C.) Sigma Rotating-platform High-flexion (RP-F) Versus the Press Fit Condylar (P.F.C.) Sigma Rotating-platform (RP) Knee Implants
Launched by DEPUY INTERNATIONAL · Aug 12, 2008
Trial Information
Current as of May 25, 2025
Terminated
Keywords
ClinConnect Summary
Primary Outcome: Change from pre-operative range of motion at 1 year between patients receiving P.F.C. Sigma RP vs P.F.C. Sigma RP-F
Secondary endpoints: Comparative evaluation of any post-operative variation between subjects receiving primary TKA with either of the above devices in terms of Knee and Osteoarthritis Scores (KOOS), American Knee Society Score (AKS), EQ-5D Score and Oxford Knee Score (OKS)
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female subjects, aged between 45 and 75 years inclusive.
- • Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.
- • Subjects who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.
- • Subjects who present with osteoarthritis that in the opinion of the clinical investigator requires a primary total knee arthroplasty.
- • Subjects who in the opinion of the Clinical Investigator are considered to be suitable for treatment with either the P.F.C Sigma RP-F or the P.F.C Sigma RP knee, according to the indications specified in the package insert leaflet.
- • Subjects who have authorised the transfer of his/her pseudonymised information to DePuy.
- Exclusion Criteria:
- • Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation.
- • Female subjects who are pregnant or lactating.
- • Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.
- • Subjects who have participated in a clinical investigation with an investigational product in the last month( 30 days).
- • Subjects who are currently involved in any injury litigation claims.
- • Subjects with a known history of poor compliance to medical treatment.
- • Subjects who have previously had an osteotomy or significant surgery in the affected knee.
About Depuy International
DePuy International, a subsidiary of Johnson & Johnson, is a leading global provider of orthopedic and surgical solutions dedicated to improving patient outcomes through innovative medical devices and technologies. With a strong commitment to advancing orthopedic care, DePuy International specializes in the development and commercialization of products for joint reconstruction, trauma, and spinal surgery. The company actively engages in clinical trials to evaluate the safety and efficacy of its products, ensuring evidence-based practices that enhance the quality of care for patients worldwide. Through collaboration with healthcare professionals and ongoing research initiatives, DePuy International strives to set new standards in orthopedic surgery and contribute to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, , Spain
Wirral, Mersyside, United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials